C-Reactive Protein in Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction

Arteriosclerosis, Thrombosis, and Vascular Biology - Tập 19 Số 4 - Trang 972-978 - 1999
John Yudkin1, Coen D.A. Stehouwer1, J.J. Emeis1, Simon W. Coppack1
1From the Centre for Diabetes and Cardiovascular Risk, Department of Medicine, University College London Medical School, G Block, Archway Wing, Whittington Hospital, Archway Road, London N19 3UA, UK (J.S.Y., S.W.C.); the Department of Medicine, Academic Hospital Vrije Universiteit and the Institute for Cardiovascular Research Vrije Universiteit, 1081 HV Amsterdam, Netherlands (C.D.A.S.); and the Gaubius Laboratory, TNO-PG, 2301 CE Leiden, Netherlands (J.J.E.).

Tóm tắt

Abstract —C-reactive protein, a hepatic acute phase protein largely regulated by circulating levels of interleukin-6, predicts coronary heart disease incidence in healthy subjects. We have shown that subcutaneous adipose tissue secretes interleukin-6 in vivo. In this study we have sought associations of levels of C-reactive protein and interleukin-6 with measures of obesity and of chronic infection as their putative determinants. We have also related levels of C-reactive protein and interleukin-6 to markers of the insulin resistance syndrome and of endothelial dysfunction. We performed a cross-sectional study in 107 nondiabetic subjects: (1) Levels of C-reactive protein, and concentrations of the proinflammatory cytokines interleukin-6 and tumor necrosis factor-α, were related to all measures of obesity, but titers of antibodies to Helicobacter pylori were only weakly and those of Chlamydia pneumoniae and cytomegalovirus were not significantly correlated with levels of these molecules. Levels of C-reactive protein were significantly related to those of interleukin-6 ( r =0.37, P <0.0005) and tumor necrosis factor-α ( r =0.46, P <0.0001). (2) Concentrations of C-reactive protein were related to insulin resistance as calculated from the homoeostasis model assessment model, blood pressure, HDL, and triglyceride, and to markers of endothelial dysfunction (plasma levels of von Willebrand factor, tissue plasminogen activator, and cellular fibronectin). A mean standard deviation score of levels of acute phase markers correlated closely with a similar score of insulin resistance syndrome variables ( r =0.59, P <0.00005), this relationship being weakened only marginally by removing measures of obesity from the insulin resistance score ( r =0.53, P <0.00005). These data suggest that adipose tissue is an important determinant of a low level, chronic inflammatory state as reflected by levels of interleukin-6, tumor necrosis factor-α, and C-reactive protein, and that infection with H pylori , C pneumoniae , and cytomegalovirus is not. Moreover, our data support the concept that such a low-level, chronic inflammatory state may induce insulin resistance and endothelial dysfunction and thus link the latter phenomena with obesity and cardiovascular disease.

Từ khóa


Tài liệu tham khảo

1988, Lab Invest, 58, 249

10.1056/NEJM199408183310709

10.1016/0021-9150(95)05716-1

10.1016/0002-9149(90)90079-G

10.1056/NEJM199503093321003

10.1161/circ.94.5.874

10.1136/bmj.312.7038.1061

10.1056/NEJM199704033361401

Koenig W Froehlich M Sund M Doering A Fischer HG Loewel H Hutchinson WL Pepys M. C-reactive protein (CRP) predicts risk of coronary heart disease (CHD) in healthy middle-aged men: results from the MONICA-Augsburg Cohort Study 1984/85–1992. Circulation . 1997;96(suppl 8):I99. Abstract.

10.1093/oxfordjournals.aje.a008963

10.1016/S0140-6736(97)03079-1

10.1042/bj2650621

1997, J Clin Endocrinol Metab, 82, 4196

10.1172/JCI117936

1995, J Clin Endocrinol, 9, 61

10.1172/JCI117899

10.1172/JCI117495

10.1097/00041433-199405030-00008

10.1055/s-0038-1648512

10.1136/bmj.311.7007.711

10.1093/oxfordjournals.eurheartj.a014934

10.1161/circ.94.5.922

10.2337/diab.37.12.1595

10.1161/atvb.15.9.1330

10.1007/BF00402183

10.1136/bmj.306.6872.240

10.1016/1056-8727(94)90039-6

10.1161/atvb.16.3.450

1989, J Lab Clin Med, 113, 586

10.1089/hyb.1994.13.205

10.3109/00365518709168882

10.1016/0049-3848(96)00021-7

10.1111/j.1574-695X.1994.tb00422.x

10.1007/BF00280883

10.2307/2531158

10.1136/bmj.312.7038.1049

10.1016/S0140-6736(96)07591-5

10.1016/S0002-8703(98)70337-0

10.1136/hrt.78.3.273

10.1161/atvb.17.10.2167

10.2337/diab.46.3.451

10.1677/jme.0.0090061

1982, Proc Natl Acad Sci U S A, 82, 912

1992, Cancer Res, 52, 4113

10.1146/annurev.iy.08.040190.001345

10.1126/science.271.5249.665

10.1161/atvb.15.1.52

10.1016/S1074-7613(00)80334-9

10.1016/S0140-6736(96)09424-X

10.2337/diab.43.11.1271

10.1126/science.7678183

10.1007/BF02342445